37,X/38,XY Mosaicism in a Cryptorchid Bengal Cat with Müllerian Duct Remnants

A 23-month-old tomcat was referred to our clinic because of male behavioral problems, cryptorchidism, and an undefined intra-abdominal organ resembling a uterus. Ultrasonography and computed tomography showed 2 fluid-filled tubular structures dorsolaterally to the bladder and connected to the pelvic urethra. The cat was castrated, and the tubular structures were surgically removed. Histology identified them as Müllerian duct remnants. The testes were hypoplastic, the epididymes and deferent ducts were normal. Cytogenetic analyses revealed the presence of a mosaic 37,X/38,XY karyotype which explains the clinical findings.

Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database

AbstractBackground It is not easy to overview pending phase 3 trials on prostate cancer (PCa), and awareness of these trials would benefit clinicians. Objective To identify all phase 3 trials on {PCa} registered in the ClinicalTrials.gov database with pending results. Design and setting On September 29, 2014, a database was established from the records for 175 538 clinical trials registered on ClinicalTrials.gov. A search of this database for the substring “prostat” identified 2951 prostate trials. Phase 3 trials accounted for 441 studies, of which 333 concerned only PCa. We selected only ongoing or completed trials with pending results, that is, for which the primary endpoint had not been published in a peer-reviewed medical journal. Results and limitations We identified 123 phase 3 trials with pending results. Trials were conducted predominantly in North America (n = 63; 51) and Europe (n = 47; 38). The majority were on nonmetastatic disease (n = 82; 67), with 37 (30) on metastatic disease and four trials (3) including both. In terms of intervention, systemic treatment was most commonly tested (n = 71; 58), followed by local treatment 34 (28), and both systemic and local treatment (n = 11; 9), with seven (6) trials not classifiable. The 71 trials on systemic treatment included androgen deprivation therapy (n = 34; 48), chemotherapy (n = 15; 21), immunotherapy (n = 9; 13), other systemic drugs (n = 9; 13), radiopharmaceuticals (n = 2; 3), and combinations (n = 2; 3). Local treatments tested included radiation therapy (n = 27; 79), surgery (n = 5; 15), and both (n = 2; 2). A limitation is that not every clinical trial is registered on ClinicalTrials.gov. Conclusion There are many {PCa} phase 3 trials with pending results, most of which address questions regarding systemic treatments for both nonmetastatic and metastatic disease. Radiation therapy and androgen deprivation therapy are the interventions most commonly tested for local and systemic treatment, respectively. Patient summary This report describes all phase 3 trials on prostate cancer registered in the ClinicalTrials.gov database with pending results. Most of these trials address questions regarding systemic treatments for both nonmetastatic and metastatic disease. Radiation therapy and androgen deprivation therapy are the interventions most commonly tested for local and systemic treatment, respectively.

Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A Population-Based, Propensity Score-Adjusted Trend Analysis

OBJECTIVE To assess whether palliative primary tumor resection in colorectal cancer patients with incurable stage IV disease is associated with improved survival. BACKGROUND There is a heated debate regarding whether or not an asymptomatic primary tumor should be removed in patients with incurable stage IV colorectal disease. METHODS Stage IV colorectal cancer patients were identified in the Surveillance, Epidemiology, and End Results database between 1998 and 2009. Patients undergoing surgery to metastatic sites were excluded. Overall survival and cancer-specific survival were compared between patients with and without palliative primary tumor resection using risk-adjusted Cox proportional hazard regression models and stratified propensity score methods. RESULTS Overall, 37,793 stage IV colorectal cancer patients were identified. Of those, 23,004 (60.9%) underwent palliative primary tumor resection. The rate of patients undergoing palliative primary cancer resection decreased from 68.4% in 1998 to 50.7% in 2009 (P < 0.001). In Cox regression analysis after propensity score matching primary cancer resection was associated with a significantly improved overall survival [hazard ratio (HR) of death = 0.40, 95% confidence interval (CI) = 0.39-0.42, P < 0.001] and cancer-specific survival (HR of death = 0.39, 95% CI = 0.38-0.40, P < 0.001). The benefit of palliative primary cancer resection persisted during the time period 1998 to 2009 with HRs equal to or less than 0.47 for both overall and cancer-specific survival. CONCLUSIONS On the basis of this population-based cohort of stage IV colorectal cancer patients, palliative primary tumor resection was associated with improved overall and cancer-specific survival. Therefore, the dogma that an asymptomatic primary tumor never should be resected in patients with unresectable colorectal cancer metastases must be questioned.

Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37.

Vitamin D has immunomodulatory properties in the defence against pathogens. Its insufficiency is a widespread feature of cystic fibrosis (CF) patients, which are repeatedly suffering from rhinovirus (RV)-induced pulmonary exacerbations.To investigate whether vitamin D has antiviral activity, primary bronchial epithelial cells from CF children were pre-treated with vitamin D and infected with RV16. Antiviral and anti-inflammatory activity of vitamin D was assessed. RV and LL-37 levels were measured in bronchoalveolar lavage (BAL) of CF children infected with RV.Vitamin D reduced RV16 load in a dose-dependent manner in CF cells (10(-7 )M, p<0.01). The antiviral response mediated by interferons remained unchanged by vitamin D in CF cells. Vitamin D did not exert anti-inflammatory properties in RV-infected CF cells. Vitamin D increased the expression of the antimicrobial peptide LL-37 up to 17.4-fold (p<0.05). Addition of exogenous LL-37 decreased viral replication by 4.4-fold in CF cells (p<0.05). An inverse correlation between viral load and LL-37 levels in CF BAL (r=-0.48, p<0.05) was observed.RV replication in primary CF bronchial cells was reduced by vitamin D through the induction of LL-37. Clinical studies are needed to determine the importance of an adequate control of vitamin D for prevention of virus-induced pulmonary CF exacerbations.

Hs. Rothschild 4° 37 - Bibliothèque de Madame la Baronne Adélaïde de Rothschild [Catalogue]

Vorbesitzer: Adélaïde de Rothschild; Freiherrlich Carl von Rothschild'sche Bibliothek Frankfurt am Main; alte Signatur: 81; Hs in 4° 37; Akzessionsnummer: X19125

Retention in care of HIV-infected pregnant and lactating women starting art under Option B+ in rural Mozambique.

OBJECTIVE In 2013, Mozambique adopted Option B+, universal lifelong antiretroviral therapy (ART) for all pregnant and lactating women, as national strategy for prevention of mother-to-child transmission of HIV. We analyzed retention in care of pregnant and lactating women starting Option B+ in rural northern Mozambique. METHODS We compared ART outcomes in pregnant ("B+pregnant"), lactating ("B+lactating") and non-pregnant-non-lactating women of childbearing age starting ART after clinical and/or immunological criteria ("own health") between July 2013 and June 2014. Lost to follow-up was defined as no contact >180 days after the last visit. Multivariable competing risk models were adjusted for type of facility (type 1 vs. peripheral type 2 health center), age, WHO stage and time from HIV diagnosis to ART. RESULTS Over 333 person-years of follow-up (of 243 "B+pregnant", 65″B+lactating" and 317 "own health" women), 3.7% of women died and 48.5% were lost to follow-up. "B+pregnant" and "B+lactating" women were more likely to be lost in the first year (57% vs. 56.9% vs. 31.6%; p<0.001) and to have no follow-up after the first visit (42.4% vs. 29.2% vs. 16.4%; p<0.001) than "own health" women. In adjusted analyses, risk of being lost to follow-up was higher in "B+pregnant" (adjusted subhazard ratio [asHR]: 2.77; 95% CI: 2.18-3.50; p<0.001) and "B+lactating" (asHR: 1.94; 95% CI: 1.37-2.74; p<0.001). Type 2 health center was the only additional significant risk factor for loss to follow-up. CONCLUSIONS Retaining pregnant and lactating women in option B+ ART was poor; losses to follow-up were mainly early. The success of Option B+ for prevention of mother-to-child transmission of HIV in rural settings with weak health systems will depend on specific improvements in counseling and retention measures, especially at the beginning of treatment. This article is protected by copyright. All rights reserved.

Bau- und Wohnungswirtschaft in Palästina 1936/37

Hans Jacobowitz

Ms. Barth. 37 - Decretalium compilatio cum novellis Innocentii IV. papae

Vorbesitzer: Johannes Bretheim; Philippus Berbach; Bartholomaeusstift Frankfurt am Main

Ms. Carm. 37 - [Sammelband in 4 Teilen: Konvolut aus Handschriften und Inkunabeln]

Vorbesitzer: Karmeliterkloster Frankfurt am Main

Na 1 Nachlass Max Horkheimer, 58 - Korrespondenzen u.a. mit Betty Drury (p. I 27, 186-333)

5 Briefe zwischen Konrad Wittwer und Max Horkheimer, 1936, 1938, 1939; 1 Brief von Max Horkheimer an Joseph Wohl, 18.08.1934; 1 Brief von Max Horkheimer an Hedwig Wollenberger, 25.02.1941; 2 Briefe zwischen Richard Wolf und Max Horkheimer, 22.10.1938, 07.11.1938; 2 Briefe zwischen Martha Wolfenstein und Max Horkheimer, 11.10.1937, 19.10.1937; 1 Brief von Clemy Wolff an Leo Löwenthal, 05.03.1941; 2 Briefe zwischen Ilse Wolff und Max Horkheimer, 29.08.1937, 03.09.1937; 1 Brief von Max Horkheimer an Howard Woolston, 25.03.1941; 1 Einladung von der Women's Conference, 1935; 1 Brief von Max Horkheimer an die Women's Conference, 15.03.1935; 1 Brief von der World Foundation an Max Horkheimer, 26.11.1937; 2 Briefe vom World Jewish Congress an Max Horkheimer, 1942, 1945; 1 Brief von Max Horkheimer an Francis Henry Russel, 28.09.1942; 1 Brief von Max Horkheimer an Dr. Opie, 28.09.1942; 1 Brief der Württembergische Hypothekenbank an Max Horkheimer, 24.12.1930; 12 Briefe zwischen Rösle Wuestholz und Max Horkheimer, 1935-1937, 1939; 1 Brief von Max Horkheimer an Frida Wunderlich, 22.11.1937; 1 Brief von Max Horkheimer an die Yale University Library, 22.12.1938; 2 Briefe zwischen Owen D. Young und Max Horkheimer, 22.04.1940, April 1940; 3 Briefe zwischen Hans Zeisel und Max Horkheimer, 21.07.1941, 1941, 1944; 2 Briefe zwischen der Zentrale Hilfsstelle für deutsche Flüchtlingskinder Prag und Max Horkheimer, 01.03.1938, 25.04.1938; 6 Briefe zwischen Gregory Zilboorg und Max Horkheimer, 1939; 16 Briefe und Beilage an Max Horkheimer und F. Pollock von Edgar Zilsel, 1939-1942; 1 Brief vom Social Science Research Counsil an Edgar Zilsel, 01.04.1940; 1 Brief von The Rockefeller Foundation an Edgar Zilsel, 20.06.1939; 9 Briefe und Beilage von Max Horkheimer und F. Pollock an Edgar Zilsel, 1939-1942 sowie Briefwechsel mit Betty Drury; 10 Briefe zwischen The Rockefeller Foundation und Max Horkheimer, 1939-1940; 1 Brief von Max Horkheimer an Edgar Zilsel, 20.06.1939; 12 Briefe zwischen Betty Drury und F. Pollock, 1939-1940; 7 Briefe zwischen Alexander Zinnemann und Max Horkheimer, 1936;

Na 1 Nachlass Max Horkheimer, 2 - Korrespondenzen u.a. an Raymond Aron (p. I 1, 206-333)

16 Briefe zwischen Ruth Nanda Anshen und Max Horkheimer, 1938-1941; 5 Briefe zwischen Peter Appel und Max Horkheimer, 1937; 1 Drucksache der Arbeitsgemeinschaft Sozialistischer Ärzte in Hessen, Juli 1949; 1 Brief der Arbeitsgemeinschaft für Soziale Betriebsgestaltung in Heidelberg an Max Horkheimer, 18.10.1949; 2 Briefe zwischen Lois Archer und Max Horkheimer, 24.07.1947, 04.08.1947; 2 Briefe zwischen Camille Arnaud und Max Horkheimer, 03.03.1946, 22.03.1946; 39 Briefe zwischen Raymond Aron und Max Horkheimer, 1935-1938; 2 Briefe zwischen Ruth Arrau und Max Horkheimer, 28.06.1949, 10.10.1949; 3 Briefe zwischen S. Aufhauser und Max Horkheimer, 1939-1941, 16.04.1941; 8 Briefe zwischen der Zeitschrift 'Aufbau' und Max Horkheimer, 1944-1944; 3 Briefe zwischen der Automobile Club of New York und Max Horkheimer, 1937, 10.08.1937;

Kundmachung: Johann Urban, von Wien gebürtig, 37 Jahre alt, katholisch ...

Welsch (Projektbearbeiter): Verurteilung des ehemaligen Geschäftsführers einer Textilfabrik und Mitgliedes der Wiener Sicherheitswache Urban (in Umwandlung der zuvor ausgesprochenen Todesstrafe) zu zwölfjähriger Zwangsarbeit wegen Aufruhrs und bewaffneten Widerstands gegen das Militär

Na 1 Nachlass Max Horkheimer, 37 - Korrespondenzen u.a. mit Dorthy I. Mulgrave (p. I 18, 335-517)

1 Brief von Margot von Mendelssohn an Max Horkheimer, 20.05.1948; 6 Briefe zwsichen Charles E. Merriam und Max Horkheimer, 1940-1941; 4 Briefe zwischen Josef Messinger und Max Horkheimer, 1940; 1 Curriculum Vitae von Alfred Meusel an Max Horkheimer; 1 Brief von Max Horkheimer an Gerhard Meyer, 17.10.1938; 3 Briefe zwischen Hans A. Meyer und Max Horkheimer´09.10.1939, 1947; 2 Briefe zwischen Julie Meyer und Max Horkheimer, 12.04.1941, 15.04.1941; 43 Briefe zwischen Hermann Meyer-Lindenberg, Oscar Meyer und Max Horkheimer sowie Briefwechsel mit Hadley Cantril; 2 Briefe zwischen Hadley Cantril und Theodor W. Adorno, 22.05.1941, 28.05.1941; 1 Brief von Jerome Michael an Margot von Mendelssohn, 10.01.1941; 2 Briefe und 2 Beilagen zwischen Joseph Mire und Max Horkheimer, 16.03.1941, 28.03.1941; 6 Briefe zwischen Mitchell, Silberberg & Knupp, Los Angeles und Max Horkheimer, 1942, 1943; 1 Brief von Friedrich Pollock an Wesley C. Mitchell, 06.08.1940; 3 Briefe zwischen Hans Mohr und Max Horkheimer, 29.03.1946, 1946; 1 Brief von Herbert Moeller Morton an Max Horkheimer, 25.02.1940; 1 Brief von Max Horkheimer an den Chairman of the Committee on General Scholarships, Cambridge Massachusetts, 01.03.1940; 2 Briefe von David H. Moses an Max Horkheimer, 1939; 1 Brief von Franz Neumann an Philip Mosley, 28.04.1941; 49 Briefe zwischen Dorthy I. Mulgrave und Max Horkheimer, 1936-1940; 1 Brief von Max Horkheimer an das Municipal Court, San Francisco, 24.12.1948;